Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes

Research output: Contribution to journalJournal articleResearchpeer-review


  • Fulltext

    Final published version, 3.55 MB, PDF document

  • Stavroula Anastasopoulou
  • Bodil Als-Nielsen
  • Joanna Banerjee
  • Mats A. Eriksson
  • Marianne Helenius
  • Mats M. Heyman
  • Inga Maria Johannsdottir
  • Olafur Gisli Jonsson
  • Stuart MacGregor
  • Marion K. Mateos
  • Chelsea Mayoh
  • Sirje Mikkel
  • Ida Hed Myrberg
  • Riitta Niinimäki
  • Mervi Taskinen
  • Goda Vaitkeviciene
  • Anna Warnqvist
  • Benjamin Wolthers
  • Arja Harila-Saari
  • Susanna Ranta

Central nervous system (CNS) toxicity is common at diagnosis and during treatment of pediatric acute lymphoblastic leukemia (ALL). We studied CNS toxicity in 1, 464 children aged 1.0-17.9 years, diagnosed with ALL and treated according to the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol. Genome-wide association studies, and a candidate single-nucleotide polymorphism (SNP; n=19) study were performed in 1, 166 patients. Findings were validated in an independent Australian cohort of children with ALL (n=797) in whom two phenotypes were evaluated: diverse CNS toxicities (n=103) and methotrexate-related CNS toxicity (n=48). In total, 135/1, 464 (9.2%) patients experienced CNS toxicity for a cumulative incidence of 8.7% (95% confidence interval: 7.31-10.20) at 12 months from diagnosis. Patients aged ≥10 years had a higher risk of CNS toxicity than had younger patients (16.3% vs. 7.4%; P<0.001). The most common CNS toxicities were posterior reversible encephalopathy syndrome (n=52, 43 with seizures), sinus venous thrombosis (n=28, 9 with seizures), and isolated seizures (n=16). The most significant SNP identified by the genome-wide association studies did not reach genomic significance (lowest P-value: 1.11x10-6), but several were annotated in genes regulating neuronal functions. In candidate SNP analysis, ATXN1 rs68082256, related to epilepsy, was associated with seizures in patients <10 years (P=0.01). ATXN1 rs68082256 was validated in the Australian cohort with diverse CNS toxicities (P=0.04). The role of ATXN1 as well as the novel SNP in neurotoxicity in pediatric ALL should be further explored.

Original languageEnglish
Issue number10
Pages (from-to)2318-2328
Number of pages11
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
© 2022 Ferrata Storti Foundation Published under a CC BY-NC license.

Number of downloads are based on statistics from Google Scholar and

No data available

ID: 329283335